Update in ITP and TTP SPOC
Immune Thrombocytopenic Purpura and Thrombotic Thrombocytopenic Purpura are both autoimmune conditions leading to low platelets, though the mechanism by which the platelets are consumed differs. The lecture will update viewers on new therapies for the treatment of ITP and TTP
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, and others who are interested in care of patients with cancer in North Carolina.
- Explain the role of thrombopoietin receptor agonists in the treatment of ITP
- Discuss the role of caplacizumab in the treatment of TTP
- Describe the optimal prophylaxis and immunizations for patients treated with prolonged corticosteroids or other immunosuppressants for ITP and TTP
Alice Ma, MD, FACP
Presenter Disclosure Information
Alice Ma, MD, FACP, has no relevant financial relationships with commercial interests as defined by the ACCME.
This Non-Credit Course does not have accreditation. It only offers general participation certificates.
- 1.00 Participation
UNC Lineberger Cancer Network certificate of participation.
Tim Poe, Director of Telehealth